These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31442285)

  • 1. Assessing the immunogenicity and toxicity of the AFPL1-conjugate nicotine vaccine using heterologous and homologous vaccination routes.
    Fraleigh NL; Oliva R; Lewicky JD; Martel AL; Acevedo R; Dagmar GR; Le HT
    PLoS One; 2019; 14(8):e0221708. PubMed ID: 31442285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeat-Dose Toxicity Study Using the AFPL1-Conjugate Nicotine Vaccine in Male Sprague Dawley Rats.
    Oliva R; Fraleigh NL; Lewicky JD; Fariñas M; Hernández T; Martel AL; Navarro I; Dagmar GR; Acevedo R; Le HT
    Pharmaceutics; 2019 Nov; 11(12):. PubMed ID: 31771151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing the Immune Response of a Nicotine Vaccine with Synthetic Small "Non-Natural" Peptides.
    Le HT; Fraleigh NL; Lewicky JD; Boudreau J; Dolinar P; Bhardwaj N; Diaz-Mitoma F; Montaut S; Fallahi S; Martel AL
    Molecules; 2020 Mar; 25(6):. PubMed ID: 32178357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New vaccines require potent adjuvants like AFPL1 and AFCo1.
    Pérez O; Lastre M; Cabrera O; del Campo J; Bracho G; Cuello M; Balboa J; Acevedo R; Zayas C; Gil D; Mora N; González D; Pérez R; González E; Barberá R; Fajardo EM; Sierra G; Solís RL; Campa C
    Scand J Immunol; 2007; 66(2-3):271-7. PubMed ID: 17635804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the immunogenicity of an intranasal vaccine against nicotine in mice using the Adjuvant Finlay Proteoliposome (AFPL1).
    Fraleigh NL; Boudreau J; Bhardwaj N; Eng NF; Murad Y; Lafrenie R; Acevedo R; Oliva R; Diaz-Mitoma F; Le HT
    Heliyon; 2016 Aug; 2(8):e00147. PubMed ID: 27622215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probing the protective effects of a conformationally constrained nicotine vaccine.
    Moreno AY; Azar MR; Koob GF; Janda KD
    Vaccine; 2012 Oct; 30(47):6665-70. PubMed ID: 22963803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal immunization using proteoliposome and cochleate structures from Neisseria meningitidis serogroup B induce mucosal and systemic responses.
    Campo JD; Zayas C; Romeu B; Acevedo R; González E; Bracho G; Cuello M; Cabrera O; Balboa J; Lastre M
    Methods; 2009 Dec; 49(4):301-8. PubMed ID: 19410000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering of a hybrid nanoparticle-based nicotine nanovaccine as a next-generation immunotherapeutic strategy against nicotine addiction: A focus on hapten density.
    Zhao Z; Powers K; Hu Y; Raleigh M; Pentel P; Zhang C
    Biomaterials; 2017 Apr; 123():107-117. PubMed ID: 28167389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants.
    Chen X; Pravetoni M; Bhayana B; Pentel PR; Wu MX
    Vaccine; 2012 Dec; 31(1):159-64. PubMed ID: 23123021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing immunogenicity of a 3'aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates.
    McCluskie MJ; Pryde DC; Gervais DP; Stead DR; Zhang N; Benoit M; Robertson K; Kim IJ; Tharmanathan T; Merson JR; Davis HL
    Int Immunopharmacol; 2013 May; 16(1):50-6. PubMed ID: 23562759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alum as an adjuvant for nanoparticle based vaccines: A case study with a hybrid nanoparticle-based nicotine vaccine.
    Hu Y; Smith D; Zhao Z; Harmon T; Pentel PR; Ehrich M; Zhang C
    Nanomedicine; 2019 Aug; 20():102023. PubMed ID: 31181264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expecting the antinicotine vaccine].
    Didilescu C
    Pneumologia; 2009; 58(3):177-8. PubMed ID: 19817315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccines against nicotine.
    Cerny EH; Cerny T
    Hum Vaccin; 2009 Apr; 5(4):200-5. PubMed ID: 19276649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum.
    de Villiers SH; Cornish KE; Troska AJ; Pravetoni M; Pentel PR
    Vaccine; 2013 Dec; 31(52):6185-93. PubMed ID: 24176492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced immunogenicity of a bivalent nicotine vaccine.
    Keyler DE; Roiko SA; Earley CA; Murtaugh MP; Pentel PR
    Int Immunopharmacol; 2008 Nov; 8(11):1589-94. PubMed ID: 18656557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of a multivalent peptide vaccine for nicotine addiction.
    Zeigler DF; Roque R; Clegg CH
    Vaccine; 2019 Mar; 37(12):1584-1590. PubMed ID: 30772068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A nanoparticle-based nicotine vaccine and the influence of particle size on its immunogenicity and efficacy.
    Zhao Z; Hu Y; Hoerle R; Devine M; Raleigh M; Pentel P; Zhang C
    Nanomedicine; 2017 Feb; 13(2):443-454. PubMed ID: 27520729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescreening of Nicotine Hapten Linkers in Vitro To Select Hapten-Conjugate Vaccine Candidates for Pharmacokinetic Evaluation in Vivo.
    Arutla V; Leal J; Liu X; Sokalingam S; Raleigh M; Adaralegbe A; Liu L; Pentel PR; Hecht SM; Chang Y
    ACS Comb Sci; 2017 May; 19(5):286-298. PubMed ID: 28383252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of anti-Haemophilus influenzae type b CRM197 conjugate following mucosal vaccination with oligodeoxynucleotide containing immunostimulatory sequences as adjuvant.
    Mariotti S; Teloni R; von Hunolstein C; Romagnoli G; Orefici G; Nisini R
    Vaccine; 2002 May; 20(17-18):2229-39. PubMed ID: 12009277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing Neutralized Nicotine Distribution Using Mice Vaccinated with the Mucosal Conjugate Nicotine Vaccine.
    Fraleigh NL; Lewicky JD; Martel AL; Diaz-Mitoma F; Le HT
    Vaccines (Basel); 2021 Feb; 9(2):. PubMed ID: 33546163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.